Sunshine Biopharma Shares Owned By Institutions vs. Gross Profit
| SBFM Stock | USD 3.04 0.60 24.59% |
For Sunshine Biopharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Sunshine Biopharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Sunshine Biopharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Sunshine Biopharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Sunshine Biopharma over time as well as its relative position and ranking within its peers.
Sunshine |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sunshine Biopharma. If investors know Sunshine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sunshine Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (127.90) | Revenue Per Share 197.42 | Quarterly Revenue Growth 0.416 | Return On Assets (0.11) | Return On Equity (0.18) |
The market value of Sunshine Biopharma is measured differently than its book value, which is the value of Sunshine that is recorded on the company's balance sheet. Investors also form their own opinion of Sunshine Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sunshine Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sunshine Biopharma's market value can be influenced by many factors that don't directly affect Sunshine Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sunshine Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sunshine Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sunshine Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Sunshine Biopharma Gross Profit vs. Shares Owned By Institutions Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Sunshine Biopharma's current stock value. Our valuation model uses many indicators to compare Sunshine Biopharma value to that of its competitors to determine the firm's financial worth. Sunshine Biopharma is rated below average in shares owned by institutions category among its peers. It is rated below average in gross profit category among its peers fabricating about 920,551 of Gross Profit per Shares Owned By Institutions. At this time, Sunshine Biopharma's Gross Profit is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Sunshine Biopharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Sunshine Gross Profit vs. Shares Owned By Institutions
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Sunshine Biopharma |
| = | 1.84 % |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Sunshine Biopharma |
| = | 1.7 M |
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Sunshine Gross Profit Comparison
Sunshine Biopharma is currently under evaluation in gross profit category among its peers.
Sunshine Biopharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Sunshine Biopharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Sunshine Biopharma will eventually generate negative long term returns. The profitability progress is the general direction of Sunshine Biopharma's change in net profit over the period of time. It can combine multiple indicators of Sunshine Biopharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 696.1 K | 730.9 K | |
| Operating Income | -4.8 M | -4.5 M | |
| Income Before Tax | -4.1 M | -4.3 M | |
| Net Loss | -4.5 M | -4.7 M | |
| Income Tax Expense | 395.2 K | 414.9 K | |
| Total Other Income Expense Net | 674.4 K | 708.1 K | |
| Net Loss | -26.8 M | -25.4 M | |
| Net Loss | -24.1 M | -22.9 M | |
| Net Interest Income | 602.3 K | 632.4 K | |
| Interest Income | 736 K | 460 K | |
| Change To Netincome | 21.1 M | 22.1 M | |
| Net Loss | (370.41) | (388.93) | |
| Income Quality | 1.95 | 2.04 | |
| Net Income Per E B T | 1.10 | 0.77 |
Sunshine Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Sunshine Biopharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Sunshine Biopharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Sunshine Biopharma's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Sunshine Biopharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run USA ETFs Now
USA ETFsFind actively traded Exchange Traded Funds (ETF) in USA |
| All Next | Launch Module |
Use Investing Themes to Complement your Sunshine Biopharma position
In addition to having Sunshine Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Robots And Drones Thematic Idea Now
Robots And Drones
Large technology companies that are involved in development and manufacturing of drones, robots, or robotic equipment across mechanical engineering, electrical engineering, mathematics and computer science fields. Drones and robotics are projected to significantly grow in demand in the next 5 years. The Robots And Drones theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Robots And Drones Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map. To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
To fully project Sunshine Biopharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Sunshine Biopharma at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Sunshine Biopharma's income statement, its balance sheet, and the statement of cash flows.